Heart Failure Patients Benefit From MitraClip Therapy [30-8-2011 10:00:00]

home | about webfeeds | feedback | submit feed

Heart Failure Patients Benefit From MitraClip Therapy

30-8-2011 10:00:00 @ Health News from Medical News Today

Results of an observational study presented at the European Society of Cardiology (ESC) meeting in Paris demonstrate that the percutaneous catheter-based MitraClip treatment improves symptoms and promotes reverse left ventricular (LV) remodeling in p...
<…>
...nization therapy (CRT). The trial, called PERMIT-CARE, is an investigator-led study evaluating the safety and efficacy of MitraClip treatment in 51 patients with clinically significant functional mitral regurgitation (FMR) at seven European centers..

goto original article »

More evidence for MitraClip benefit in frail patients with mitral regurgitation

NEW YORK (Reuters Health) - Two new papers say MitraClip helps improve clinical and echocardiographic outcomes in patients with mitral regurgitation (MR) who don't respond well to maximal drug and device therapy and who aren't candidates for surgery....(read more)

22-11-2011

Heart Failure Patients May Benefit From Testosterone Supplements

Testosterone supplements helped heart failure patients breathe better and exercise more, according to research in Circulation Heart Failure, an American Heart Association journal. Researchers analyzed four randomized clinical trials of patients with moderate to severe chronic heart failure. Patients were given commercial testosterone supplements by injection, patch or gel. Based on the analysis of these studies, those who received supplemental testosterone scored 50 percent better in a six-minute walking test than those receiving placebo...

19-4-2012

Can Omecamtiv Mecarbil Help Heart Failure Patients? Too Early To Tell

An article published in the Lancet revealed results of two clinical trials of omecamtiv mecarbil, a drug that according to researchers could one-day benefit heart failure patients by assisting the heart to contract more easily. Omecamtiv mecarbil, developed in San Francisco, activates a protein that increases the contraction of the heart muscle. First clinical trials indicate that it could help patients with stable systolic heart failure. Heart failure is defined as the inability of the heart to supply sufficient blood flow meet the needs of the body...

21-8-2011